Physician profile
Luis Melgar
NPI 1497701965
$23,185.18
in general payments reported to CMS, 2019-2025
53 companies · $2,556 in 2025
The $2,556 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,973 · 2020: $2,870 · 2021: $3,358 · 2022: $3,997 · 2023: $3,511 · 2024: $3,920 · 2025: $2,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,986.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,311.94 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,688.54 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $1,545.11 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,544.91 | 2019-2025 | Dupixent |
| Novo Nordisk INC | $1,467.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Grifols USA, LLC | $1,386.42 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Csl Behring | $1,260.08 | 2019-2025 | Haegarda, Hizentra, Kcentra |
| Amgen INC. | $1,218.88 | 2019-2025 | Tezspire, Repatha, Otezla |
| Genzyme Corporation | $1,093.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $781.03 | 2020-2025 | Cuvitru, Hyqvia |
| Lilly USA, LLC | $538.49 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $525.37 | 2021-2023 | |
| Biocryst US Sales Co., LLC | $384.26 | 2021-2025 | Orladeyo |
| Alk-Abello, INC | $369.72 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $368.81 | 2020-2025 | Rexulti |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Melgar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.